Nuveen LLC Makes New Investment in Enhabit, Inc. $EHAB

Nuveen LLC purchased a new position in shares of Enhabit, Inc. (NYSE:EHAB) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 201,681 shares of the company’s stock, valued at approximately $1,773,000. Nuveen LLC owned about 0.40% of Enhabit as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Deerfield Management Company L.P. Series C increased its position in Enhabit by 0.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,010,972 shares of the company’s stock worth $39,136,000 after buying an additional 13,226 shares during the last quarter. Vanguard Group Inc. increased its position in Enhabit by 1.6% during the first quarter. Vanguard Group Inc. now owns 2,960,343 shares of the company’s stock worth $26,021,000 after buying an additional 47,640 shares during the last quarter. AREX Capital Management LP increased its position in Enhabit by 2.0% during the fourth quarter. AREX Capital Management LP now owns 2,490,795 shares of the company’s stock worth $19,453,000 after buying an additional 48,874 shares during the last quarter. Systematic Financial Management LP increased its position in Enhabit by 8.6% during the fourth quarter. Systematic Financial Management LP now owns 1,996,113 shares of the company’s stock worth $15,590,000 after buying an additional 157,914 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Enhabit by 12.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,953,941 shares of the company’s stock worth $15,260,000 after buying an additional 213,774 shares during the last quarter.

Wall Street Analysts Forecast Growth

Separately, UBS Group decreased their target price on Enhabit from $10.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 8th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.67.

Enhabit Stock Down 0.3%

NYSE EHAB opened at $7.90 on Friday. The business has a fifty day moving average price of $7.57 and a two-hundred day moving average price of $8.48. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.57 and a quick ratio of 1.57. Enhabit, Inc. has a fifty-two week low of $6.47 and a fifty-two week high of $10.90. The stock has a market capitalization of $400.20 million, a PE ratio of -2.96 and a beta of 1.68.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.03. The company had revenue of $266.10 million during the quarter, compared to the consensus estimate of $263.39 million. Enhabit had a negative net margin of 12.84% and a positive return on equity of 2.72%. Equities analysts expect that Enhabit, Inc. will post 0.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ryan Solomon acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $7.64 per share, for a total transaction of $76,400.00. Following the completion of the acquisition, the chief financial officer directly owned 193,468 shares of the company’s stock, valued at approximately $1,478,095.52. This trade represents a 5.45% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 3.40% of the stock is owned by insiders.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.